- Home
- CHN vs BDTX Comparison
CHN vs BDTX Comparison
Compare CHN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- BDTX
- Stock Information
- Founded
- CHN 1992
- BDTX 2014
- Country
- CHN United States
- BDTX United States
- Employees
- CHN N/A
- BDTX N/A
- Industry
- CHN Investment Managers
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHN Finance
- BDTX Health Care
- Exchange
- CHN Nasdaq
- BDTX Nasdaq
- Market Cap
- CHN 153.9M
- BDTX 181.4M
- IPO Year
- CHN N/A
- BDTX 2020
- Fundamental
- Price
- CHN $16.90
- BDTX $2.83
- Analyst Decision
- CHN
- BDTX Strong Buy
- Analyst Count
- CHN 0
- BDTX 5
- Target Price
- CHN N/A
- BDTX $13.40
- AVG Volume (30 Days)
- CHN 31.8K
- BDTX 863.4K
- Earning Date
- CHN 01-01-0001
- BDTX 08-07-2025
- Dividend Yield
- CHN 0.19%
- BDTX N/A
- EPS Growth
- CHN N/A
- BDTX N/A
- EPS
- CHN N/A
- BDTX 0.25
- Revenue
- CHN N/A
- BDTX $70,000,000.00
- Revenue This Year
- CHN N/A
- BDTX N/A
- Revenue Next Year
- CHN N/A
- BDTX N/A
- P/E Ratio
- CHN N/A
- BDTX $11.38
- Revenue Growth
- CHN N/A
- BDTX N/A
- 52 Week Low
- CHN $9.00
- BDTX $1.20
- 52 Week High
- CHN $12.98
- BDTX $6.43
- Technical
- Relative Strength Index (RSI)
- CHN 66.99
- BDTX 53.48
- Support Level
- CHN $16.71
- BDTX $2.56
- Resistance Level
- CHN $17.32
- BDTX $2.98
- Average True Range (ATR)
- CHN 0.26
- BDTX 0.16
- MACD
- CHN 0.01
- BDTX 0.02
- Stochastic Oscillator
- CHN 73.58
- BDTX 69.42
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.